Ageing Science


Tuesday 4th May
Wednesday 5th May
Thursday 6th May
Friday 7th May

Tuesday 4th May


13:00 CET 12:00 BST 07:00 ET

Virtual meetings begin.
Life Lab Showcases and Virtual Posters available for viewing.


15-16 CET 14-15 BST 09-10 ET

Special session: Longevity revolution

Sergey Young, Founder, Longevity Vision Fund

Sergey Young, Founder, Longevity Vision Fund

 

Wednesday 5th May


12-13 CET 11-12 BST 06-07 ET

Roundtable: Changing the narrative on ageing science to secure funding for fundamental research

COVID-19 has changed the narrative on the biology of ageing and its impact on health. This session explores how to better communicate the concept of ageing science to funding bodies in the wake of COVID-19, encouraging open dialogue between researchers and funding bodies.

Joao Pedro De Magalhaes, Profession, Institute of Ageing and Chronic Disease, University of Liverpool
Claire Stewart, Professor of Stem Cell Biology, Stem Cells, Ageing and Molecular Physiology Unit, Liverpool John Moores University
Moderator: Lynne Cox, Associate Professor, University of Oxford

Joao Pedro De Magalhaes, Profession, Institute of Ageing and Chronic Disease, University of Liverpool    Claire Stewart, Professor of Stem Cell Biology, Stem Cells, Ageing and Molecular Physiology Unit, Liverpool John Moores University    Lynne Cox, Associate Professor, University of Oxford


13-14 CET 12-13 BST 07-08 ET

Speed Networking

Your opportunity to meet fellow longevity enthusiasts across science, business, finance and technology. Participants are split into small groups for 5 minutes at a time, just enough for initial introductions, before being moved into another group. A brilliant way to meet a high volume of potential business partners and collaborators in a relaxed, informal setting, paving the way for more formal meetings throughout


15-16 CET 14-15 BST 09-10 ET

Roundtable: What has COVID taught us about the biology of ageing?

Why are older people disproportionally affected by COVID? Why does COVID appear to accelerate the ageing process? How does the biology of long COVID differ and how does that advance our understanding of the biology of ageing? This session looks at everything we’ve learned in the past twelve months about COVID and the biology of ageing.

Janet Lord, Director of the Institute of Inflammation and Ageing, University of Birmingham
James Kirkland, Director of the Robert and Arlene Kogod Centre on Aging, Mayo Clinic; President Elect, American Federation for Aging
Moderator: Nir Barzilai, Director, Institute for Aging Research, Albert Einstein College of Medicine

Janet Lord, Director of the Institute of Inflammation and Ageing, University of Birmingham    James Kirkland, Director of the Robert and Arlene Kogod Centre on Aging, Mayo Clinic; President Elect, American Federation for Aging    Nir Barzilai, Director, Institute for Aging Research, Albert Einstein College of Medicine


16-17 CET 15-16 BST 10-11 ET

Webinar: Advances in novel discovery tools and delivery systems for ageing science applications

Ageing science demands a new set of drug discovery and delivery tools. This session explores novel drug discovery and delivery systems and how they are being applied to improve ageing science research.

Michael Zemel, Founder and Chief Scientific Officer, Nusirt
Moderator: Marc Ramis Castelltort, Co-Founder and Board Member, Senolytic Therapeutics; Co-Founder and CEO, Rejuversen AG

Michael Zemel, Founder and Chief Scientific Officer, Nusirt    Marc Ramis Castelltort, Co-Founder and Board Member, Senolytic Therapeutics; Co-Founder and CEO, Rejuversen AG


17-18 CET 16-17 BST 11-12 ET

Roundtable: What have we learned from setbacks and how to move the field forward post-COVID

2020 was a year of massive disruption for ageing science. On one hand, COVID-19 offered a new paradigm in which to study and explain the benefits of ageing science to investors, healthcare providers and regulators. On the other, two high profile trials didn’t deliver the results that were needed to propel the field into the mainstream. This session looks at what was learned and how to move forward.

Natalia Novac, Senior Director, Emerging Technologies and Innovation, Corporate Business Development, Eli Lilly

Natalia Novac, Senior Director, Emerging Technologies and Innovation, Corporate Business Development, Eli Lilly


18-19 CET 17-18 BST 12-13 ET

Webinar: Investing in longevity biotech – market opportunities, gaps and priorities

The worlds’ most prominent investors in longevity biotech share their thoughts on the biggest areas of opportunity, gaps in the market and framing priorities to bring more investment into the field.

Greg Baily, CEO, Juvenescence
Aubrey De Grey, Co-Founder and Chief Science Officer, SENS Foundation
Ronjon Nag, Managing Director and Founder, R42 Group

Greg Baily, CEO, Juvenescence    Aubrey De Grey, Co-Founder and Chief Science Officer, SENS Foundation     Ronjon Nag, Managing Director and Founder, R42 Group

 

Thursday 6th May


13-14 CET 12-13 BST 07-08 ET

Cross Sector Roundtable: Understanding the science of ageing and what it means for financial services

An opportunity for those in financial longevity, and biological longevity, to meet and exchange expertise. The roundtable will include a brief presentation from a representative from each side of the fence on a key problem that their industry is facing, and subsequent moderated discussion will explore how collaboration between science and financial services could help to solve problems on both sides.


14-15 CET 13-14 BST 08-09 ET

Webinar: Real-world applications of ageing biology in aesthetics, nutrition and consumer health

Ageing science is becoming increasingly prevalent in life sciences, aesthetics, nutrition and consumer health. This session explores how assorted disciplines are incorporating the biology of ageing into research and development of new products to enhance human healthspan.

Stephanie Manson-Brown, Head of Clinical Development, VP Allergan Aesthetics R&D, AbbVie
Sibylle Jager, Scientific Directorate Manager, L’Oreal

Stephanie Mason-Brown, Head of Clinical Development, VP Allergan Aesthetics R&D, AbbVie    Sibylle Jager, Scientific Directorate Manager, L’Oreal


15-16 CET 14-15 BST 09-10 ET

Roundtable: Novel therapeutic approaches

The field is bursting with novel approaches to harness the biology of ageing to extend healthspan. This session looks at novel therapeutic approaches including targeting mRNA, mitochondria, senomorphics and epigenetic modifications.

Reenie McCarthy, Chief Executive Officer, Stealth Bio
Lorna Harries, Chief Scientific Officer, Senisca

Reenie McCarthy, Chief Executive Officer, Stealth Bio    Lorna Harries, Chief Scientific Officer, Senisca


16-17 CET 15-16 BST 10-11 ET

Webinar: Roadmap to commercialisation – examining clinical and regulatory pathways for longevity therapeutics

This session examines how to overcome clinical and regulatory challenges for a new therapeutic class.

Thomas Hughes, Chief Executive Officer, Navitor
Moderator: Steven Braithwaite, Chief Scientific Officer, Alkahest

Thomas Hughes, Chief Executive Officer, Navitor    Steven Braithwaite, Chief Scientific Officer, Alkahest


17-18 CET 16-17 BST 11-12 ET

Roundtable: Creating consensus on the Biology of Ageing Paradigm

In 2020 a survey of leading academics in the field of ageing science acknowledged a lack of consensus on a biology of ageing paradigm, and the need for an agreed interdisciplinary framework. This roundtable attempts to establish agreement on a common paradigm in ageing biology including vocabulary, credibility framework and guiding principles.

Thomas Rando, Co-Founder, Fountain Therapeutics
Moderator: Samuel Argus, Chief Medical Officer, Biophytis

Thomas Rando, Co-Founder and Chair of Board of Directors, Fountain Therapeutics    Samuel Argus, Chief Medical Officer, Biophytis

 

Friday 7th May


13:00 CET 12:00 BST 07:00 ET

Virtual meetings begin.
Life Lab Showcases and Virtual Posters available for viewing.

DOWNLOAD BROCHURE